MTOR and renal cell carcinoma: Current standard of care includes diverse treatment modalities such as hormonal therapy in prostate cancer, chemotherapy for urothelial and testicular cancer and targeted treatment of vascular–endothelial growth factor and mammalian target of rapamycin (mTOR) signaling in RCC.